米国における肺胞状横紋筋肉腫の生存予測因子
Akef Obeidat1, Tarek Ziad Arabi1, Aliaa Amr1
1College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Background:
Alveolar rhabdomyosarcoma (ARMS) is an aggressive subtype of rhabdomyosarcoma with generally poorer outcomes than embryonal rhabdomyosarcoma. We analyzed a large contemporary cohort to characterize survival outcomes and prognostic factors for ARMS.
Methods:
We identified patients with histologically confirmed ARMS from the Surveillance, Epidemiology, and End Results (SEER) database. Demographics, tumor characteristics (stage, primary site), and treatments (surgery, radiation, and chemotherapy) were extracted. Cancer-specific survival (CSS) was estimated with Kaplan-Meier methods and compared using log-rank tests. Cox proportional hazards models were used for univariate and multivariate analysis of prognostic factors, with results reported as hazard ratios (HR) and 95% confidence intervals (CI).
Results:
A total of 592 ARMS patients were included [median age 14 years (interquartile range 7-25); 52% male; 73% White]. Primary tumors most commonly arose in extremities or trunk (64%), followed by head and neck sites (26%) and genitourinary locations (5%). Most patients received multimodal therapy: 44% underwent surgical resection, 70% received radiotherapy, and 92% received chemotherapy. The 5-year CSS for the entire cohort was approximately 43%. Distant metastasis was the strongest independent adverse prognostic factor (aHR: 2.9, 95% CI 2.13-3.92, P < 0.001), and regional nodal involvement also independently worsened CSS (aHR: 1.46, 95% CI 1.07-1.99, P = 0.016) compared to localized disease. Older age (≥20) at diagnosis was associated with higher mortality risk (aHR: 1.82 vs. age <10, P < 0.001). Notably, the use of surgery (aHR: 0.74, P = 0.031) and radiation therapy (aHR: 0.62, P < 0.001) were independently associated with improved CSS after controlling for stage and age.
Conclusions:
In this large population-based study, ARMS survival remains poor, especially for patients with metastatic disease or in older age groups. Distant metastases and age ≥20 were associated with markedly inferior outcomes, while local therapy with surgery and radiation conferred significant survival benefit.
関連する概念動画
Cancer Survival Analysis
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Comparing the Survival Analysis of Two or More Groups


